The South Korean government passed the Bioethics and Biosafety Act, known henceforth as the Bioethics Act, in 2003 and it took effect in 2005. South Korea's Ministry of Health and Welfare proposed the law to the South Korean National Assembly to allow the progress of biotechnology and life sciences research in South Korea while protecting human research subjects with practices such as informed consent. The Bioethics Act establishes a National Bioethics Committee in Seoul, South Korea. The Bioethics Act is the first law in South Korea to regulate research on embryonic stem cells and in vitro fertilization. Most South Korean bioethical policies rely on this act and its provisions.

Edward Donnall Thomas, an American physician and scientist, gained recognition in the scientific community for conducting the first bone marrow transplant, a pioneering form of hematopoietic stem cell transplantation (HSCT). Bone marrow transplants are considered to be the first successful example of tissue engineering, a field within regenerative medicine that uses hematopoietic stem cells (HSCs) as a vehicle for treatment. Prior to Thomas's groundbreaking work, most blood-borne diseases, including certain inherited and autoimmune diseases, were considered lethal.

'On the Permanent Life of Tissues outside of the Organism' reports Alexis Carrel's 1912 experiments on the maintenance of tissue in culture media. At the time, Carrel was a French surgeon and biologist working at the Rockefeller Institute in New York City. In his paper, Carrel reported that he had successfully maintained tissue cultures, which derived from connective tissues of developing chicks and other tissue sources, by serially culturing them. Among all the tissue cultures Carrel reported, one was maintained for more than two months, whereas previous efforts had only been able to keep tissues in vitro for three to fifteen days. Carrel’s experiments contributed to the development of long-term tissue culture techniques, which were useful in the study of embryology and eventually became instrumental in stem cell research. Despite later evidence to the contrary, Carrel believed that as long as the tissue culture method was accurately applied, tissues kept outside of the organisms should be able to divide indefinitely and have permanent life.

Keith Henry Stockman Campbell studied embryo growth and cell differentiation during the twentieth and twenty-first centuries in the UK. In 1995, Campbell and his scientific team used cells grown and differentiated in a laboratory to clone sheep for the first time. They named these two sheep Megan and Morag. Campbell and his team also cloned a sheep from adult cells in 1996, which they named Dolly. Dolly was the first mammal cloned from specialized adult (somatic) cells with the technique of somatic cell nuclear transfer (SCNT). Campbell helped develop cloning techniques that used a common form of connective tissue cells (fibroblasts). Besides working at the Roslin Institute, in Edinburgh, Scotland, for most of his career, Campbell also taught at the University of Nottingham in Nottingham, England.

In 2006, Kazutoshi Takahashi and Shinya Yamanaka reprogrammed mice fibroblast cells, which can produce only other fibroblast cells, to become pluripotent stem cells, which have the capacity to produce many different types of cells. Takahashi and Yamanaka also experimented with human cell cultures in 2007. Each worked at Kyoto University in Kyoto, Japan. They called the pluripotent stem cells that they produced induced pluripotent stem cells (iPSCs) because they had induced the adult cells, called differentiated cells, to become pluripotent stem cells through genetic manipulation. Yamanaka received the Nobel Prize in Physiology or Medicine in 2012, along with John Gurdon, as their work showed scientists how to reprogram mature cells to become pluripotent. Takahashi and Yamanaka's 2006 and 2007 experiments showed that scientists can prompt adult body cells to dedifferentiate, or lose specialized characteristics, and behave similarly to embryonic stem cells (ESCs).

The US President's Council on Bioethics was an organization headquartered in Washington D.C. that was chartered to advise then US President George W. Bush on ethical issues related to biomedical science and technology. In November 2001, US President George W. Bush created the President's Council on Bioethics (PCB). Convened during a nationwide cloning and embryonic stem cell research debate, the Council stated that it worked to address arguments about ethics from many different perspectives. The organization enacted a model for analyzing bioethical issues through deliberation instead of through the consensus approach. US President Barack Obama replaced the PCB in 2009 with his Presidential Commission for the Study of Bioethical Issues.

Established in tandem with Singapore's national Biomedical Sciences Initiatives, the Bioethics Advisory Committee (BAC) was established by the Singapore Cabinet in December 2000 to examine the potential ethical, legal, and social issues arising from Singapore's biomedical research sector, and to recommend policy to Singapore's government. BAC's deliberations on embryonic stem cell research helped shape the government policies that helped Singapore pursue its goal of becoming one of the biggest investors of embryonic stem cell research in the early twenty-first century.

To educate its citizens about research into chimeras made from human and non-human animal cells, the United Kingdom's Human Fertilisation Embryology Authority published the consultation piece Hybrids and Chimeras: A Consultation on the Ethical and Social Implications of Creating Human/Animal Embryos in Research, in 2007. The document provided scientific and legal background, described ethical and social issues associated with research using part-human part-animal embryos, supplied a questionnaire for citizens to return to the HFEA with their opinions, and offered a list of resources for further reading to stimulate public debate. The strategy of surveying the public provided a template for developing further policy in the United Kingdom and other countries, as well as for educating citizens on embryological research.

In 2004, a team of researchers at Tufts-New England Medical Center in Boston, Massachusetts, investigated the fetal cells that remained in the maternal blood stream after pregnancy. The results were published in Transfer of Fetal Cells with Multilineage Potential to Maternal Tissue. The team working on that research included Kiarash Khosrotehrani, Kirby L. Johnson, Dong Hyun Cha, Robert N. Salomon, and Diana W. Bianchi. The researchers reported that the fetal cells passed to a pregnant woman during pregnancy could develop into multiple cell types in her organs. They studied these differentiated fetal cells in a cohort of women fighting different diseases. The researchers found that the fetal cells in the women differentiated into different cell types under the influence of maternal tissues, and that those differentiated cells concentrated in the tissue surrounding diseased tissues. According to the team, this response could be a therapeutic response to the disease in the once pregnant woman. The research indicated the long lasting effects of pregnancy in a woman's body.

In 2007, the Human Fertilisation and Embryology Authority in London, UK, published Hybrids and Chimeras: A Report on the Findings of the Consultation, which summarized a public debate about research on, and suggested policy for, human animal chimeras. The HFEA formulated the report after conducting a series of surveys and debates from earlier in 2007. The HFEA issued a statement in September 2007, followed by an official report published on 1 October 2007. Their report on human-animal chimeras set a worldwide precedent for discussions of the ethical use of those embryos in labs. The HFEA's report led the UK government to pass legislature about the use of human-animal cytoplasmic hybrid embryos for research in the UK.